A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
Urethral atrophy occurs significantly more frequently and earlier in radical prostatectomy patients who receive radiation therapy after rather than before artificial urinary sphincter insertion, a study found.
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
Sarcopenia prior to nerve-sparing robot-assisted radical prostatectomy is significantly associated with sexual dysfunction after the surgery, according to investigators.
After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.
Single-center study reveals that robot-assisted radical prostatectomy is associated with superior biochemical recurrence-free survival and a lower positive surgical margin rate.
Among men undergoing radical prostatectomy for Gleason score 6 prostate cancer, men older than 65 are more likely than younger men to have higher grade or stage disease found at the time of surgery, a study found.
Radical prostatectomy (RP) may provide small very long-term reductions in death risk compared with observation for patients with clinically localized prostate cancer (PCa), according to investigators. In an extended follow-up of 731 participants in the randomized Prostate Cancer Intervention versus Observation Trial (PIVOT), men assigned to undergo RP had an 8% reduction in the relative…
Very high initial PSA levels in patients undergoing radical prostatectomy (RP) for high-risk clinically localized prostate cancer (PCa) are associated with worse oncologic outcomes, according to a new study. Men with initial PSA levels of 50 ng/mL or higher have significantly worse rates of biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS), and cancer-specific survival (CSS)…
